Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HBH1
UPID:
DEFM_HUMAN
Alternative names:
Polypeptide deformylase
Alternative UPACC:
Q9HBH1; Q8WUN6
Background:
Peptide deformylase, mitochondrial, also known as Polypeptide deformylase, plays a crucial role in protein synthesis. It specifically removes the formyl group from the N-terminal Met of newly synthesized proteins, a vital step in the maturation and functionality of proteins within the cell.
Therapeutic significance:
Understanding the role of Peptide deformylase, mitochondrial could open doors to potential therapeutic strategies. Its unique function in protein synthesis presents an intriguing target for drug discovery, aiming to modulate protein production in diseases.